Athira Pharma, Inc. announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer. Dr. Church joined Athira in 2016 and most recently served as Executive Vice President, Research. In his current role, he leads the discovery and preclinical development teams and is responsible for leading the expansion and development of Athira's novel platform of small molecule therapeutic candidates, which offers the potential to address a wide range of neurological diseases.

Dr. Church received his B.S. in Microbiology from the University of Idaho and his Ph.D. in Molecular Biosciences from Washington State University.